One-glance verdict
Overvalued
$5.02 our estimate vs market $13.20
Wall Street consensus: $15.00 (198.8% higher than our fair-value estimate)
163% above our estimate, beyond the bull case
Fundamentals snapshot
Straumann Holding AG
SAUHY · PNK · Healthcare · Medical Instruments & Supplies
Current price
$13.20
52-week range
$9.44 - $13.61
Market cap
$21.40B
Balance sheet
Healthy
36.00x Strong cushion
Net debt $73.73M. Interest coverage shows how many times profit covers the interest bill.
What stands out
3 Rewards
1 Risk
3 rewards · 1 risks
- Reward Revenue grew 4.1% last year.
- Reward Returns 17.0% on equity, ahead of 83% of its peers.
- Reward Free cash flow was positive in 4/10 years.
- Risk Insider ownership is only 0.0% (peer median: 0.6%).
What this company does
Straumann Holding AG
Straumann Holding AG makes products to fix and straighten teeth, like implants and clear aligners, selling them worldwide. Most of their money comes from selling these dental solutions, which are important because they help dentists improve patient smiles and oral health.
How the company got here
Straumann Holding AG started in 1954 as a research institute focused on alloys, initially for timing instruments and later for medical applications like bone implants. A significant shift occurred in the 1970s when the company began adapting its expertise to dental prosthetics, leading to the production of its first dental implant in 1974. The company went public on the Swiss stock exchange in 1998, which fueled further expansion through strategic acquisitions in areas like oral tissue regeneration and digital dentistry. This evolution transformed Straumann from a materials science company into a global leader in dental solutions.
What it actually does
Straumann Holding AG is a global leader in providing solutions for tooth replacement, restoration, and the prevention of tooth loss. They develop, manufacture, and sell a wide range of products, including dental implants, prosthetic components, biomaterials, and digital equipment used by dentists and dental laboratories. The company also offers training and educational services to dental professionals worldwide, aiming to improve patient outcomes and confidence through advanced oral care.
Dental Implantology
This is Straumann's core business, focusing on creating solutions for replacing missing teeth with dental implants. They offer a comprehensive system that includes the implants themselves, which are small titanium posts surgically placed into the jawbone, as well as the prosthetic components that attach to the implant to form a new tooth. This segment also encompasses instruments and digital tools to aid in the precise placement and restoration process, aiming to provide long-lasting and natural-looking tooth replacements. Straumann is a leading player in this market, known for its high-quality materials and innovative implant surfaces designed to promote healing and integration with the bone.
Orthodontics
Straumann also has a significant presence in the field of orthodontics, which deals with correcting misaligned teeth and jaws. This segment includes products like clear aligners, which are custom-made, transparent trays that gradually move teeth into the desired position. This is often a more aesthetically pleasing and comfortable alternative to traditional braces for many patients. The company sees orthodontics as a complementary area, as many patients requiring dental implants may also need their teeth straightened beforehand.
Digital Dentistry & Biomaterials
This segment encompasses Straumann's investments in digital technologies and advanced materials for dental applications. This includes products like intra-oral scanners, which create digital 3D models of a patient's mouth, and CAD/CAM (Computer-Aided Design/Computer-Aided Manufacturing) systems used to design and produce custom prosthetics like crowns and bridges. They also develop and supply biomaterials, such as bone substitutes and regenerative materials, used to help preserve or rebuild bone and gum tissue, which is crucial for successful implant placement and overall oral health.
What management is betting on now
Straumann's current strategy focuses on maintaining its leadership in implantology while expanding its presence in orthodontics and digital dentistry. They are investing in digital transformation to create more efficient and predictable treatment workflows for dental professionals. Management is also prioritizing a strong company culture and sustainability initiatives, aiming to drive growth and innovation while positively impacting people and the planet. Straumann aims for significant revenue growth, underpinned by continued investment and operational excellence.
Price history
How the share price has moved
—
Loading price history…
Is it cheap or expensive?
Fair value $5.02 vs current price $13.20
Wall Street consensus is the average analyst price target: $15.00 (198.8% higher than our fair-value estimate).
Our most-likely fair value is $5.02 a share — about 62.0% below today's price of $13.20, so the stock currently looks expensive (overvalued).
Is it drowning in debt?
Healthy
Net debt $73.7M. Interest coverage 36.0x.
Net debt
$73.73M
Interest coverage
36.00x
Straumann Holding AG's profit covers its interest bill about 36.0 times over. which is stronger than most peers shown here.
Healthy
Worse cushion
Baseline
Better cushion
SAUHY
BASELINE
Straumann Holding AG
Total debt $583.01M Interest coverage 36.00x This is the baseline the peer rows are being compared against.
Total debt $7.60B Interest coverage 4.63x -87% vs SAUHY Carries about 7.8x less debt cushion than SAUHY.
Total debt $112.30M Interest coverage 36.48x +1% vs SAUHY Has roughly the same debt cushion as SAUHY.
Total debt $3.81B Interest coverage 5.05x -86% vs SAUHY Carries about 7.1x less debt cushion than SAUHY.
Total debt $1.59B Interest coverage 6.44x -82% vs SAUHY Carries about 5.6x less debt cushion than SAUHY.
Total debt $2.33B Interest coverage 2.86x -92% vs SAUHY Carries about 12.6x less debt cushion than SAUHY.
What you should know
The case for and against SAUHY
3 Rewards
1 Risk
Rewards
-
Revenue grew 4.1% last year.
-
Returns 17.0% on equity, ahead of 83% of its peers.
-
Free cash flow was positive in 4/10 years.
Risks
-
Insider ownership is only 0.0% (peer median: 0.6%).
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
45.52x
Forward P/E
27.45x
P/B
7.58x
P/S
8.12x
EV/EBITDA
28.07x
PEG ratio
1.26x
Profitability
How much profit each dollar creates
Gross margin
69.3%
Operating margin
25.1%
Net margin
14.0%
ROE
17.0%
ROA
11.0%
Health
Liquidity and balance-sheet strength
Debt / equity
0.21x
Current ratio
2.26x
Quick ratio
1.61x
Total debt
$583.01M
Total cash
$509.28M
Growth
How the business has been compounding
Revenue TTM
$3.24B
Revenue 5Y CAGR
3.9%
EPS TTM
0.29
EPS 5Y CAGR
-6.4%
Cash flow
How much cash the business throws off
Operating CF TTM
$619.05M
Free CF TTM
$344.57M
FCF margin
10.6%
Dividend
Shareholder payout
Yield
1.0%
Payout ratio
43.9%
Last ex-div date
2026-04-22